The current Food and Drug Administration-approved systemic treatments for advanced hepatocellular carcinoma (HCC) include multikinase inhibitors (tyrosine kinase inhibitor [TKI]) and immune checkpoint inhibitors (ICIs). Among ICIs. nivolumab is used as second-line therapy for advanced HCC after sorafenib failure or patient intolerance. In this case. https://thebrickes.shop/product-category/sheet-set/